University of North Carolina, Chapel Hill

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of North Carolina, Chapel Hill sits in the top decile of US sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count).

1,109 total trials 108 currently recruiting 881 completed early-phase tilt top decile by trial count

University of North Carolina, Chapel Hill: 1,109 sponsored US clinical trials, 108 recruiting.

University of North Carolina, Chapel Hill sponsors 1,109 registered US clinical trials on ClinicalTrials.gov, 108 of them currently recruiting, and 881 completed. 69 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 17 trials.

Top-decile sponsor footprint

University of North Carolina, Chapel Hill ranks in the top decile of sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

881 of 962 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,109 total, page 9 of 23

TERMINATED NA

Safety of Optimal PEEP in NSICU Patients

NCT03862027

COMPLETED

Voices From the Black Community: Hepatitis C Research Participation

NCT04202081

COMPLETED NA

Modulation of Cognitive Control Signals in Prefrontal Cortex by Rhythmic Transcranial Magnetic Stimulation

NCT03828734

COMPLETED NA

Nudges and Incentives to Enhance the Opioid Treatment Workforce

NCT03834025

COMPLETED NA

Precision Public Health: Enhancing Connections to Develop Just-in-Time Adaptive Intervention Strategies

NCT03836391

COMPLETED Phase 1

Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons

NCT03803605

COMPLETED Phase 2

Inhaled Oxytocin and HPA Axis Reactivity

NCT03593473

COMPLETED NA

Genetic-specific Effects of Fructose on Liver Lipogenesis

NCT03783195

TERMINATED NA

Reducing Binge Eating to Prevent Weight Gain in Black Women

NCT03531112

COMPLETED NA

Uniting Couples in the Treatment of Binge-Eating Disorder

NCT03784820

COMPLETED NA

Mental Health Services for Prisoners With SMI

NCT03713398

COMPLETED Phase 4

Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause"

NCT03740009

TERMINATED NA

LUPUS Brain: tACS to Target the Neurophysiology of Depression, Cognitive Deficits, and Pain in Patients With SLE

NCT04141046

COMPLETED NA

Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life

NCT03757988

COMPLETED NA

Effect of Knee Bracing on Improving Pain & Disability

NCT04044612

TERMINATED

Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study

NCT03772145

COMPLETED NA

ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)

NCT03651622

COMPLETED NA

Novel MRI Sequence- MR Fingerprinting

NCT03722459

COMPLETED NA

Tantrum Tamers 2.0: The Role of Emotion

NCT03597789

COMPLETED NA

Choline Nutritional Status: Development of a Biomarker Panel

NCT03726671

TERMINATED NA

In-vivo Effects of E-cigarette Aerosol on Innate Lung Host Defense

NCT03700892

COMPLETED NA

IFI16 is a Periodontitis Modulating Protein

NCT03513497

COMPLETED Phase 1

Effects of 20,000 EU of Clinical Center Reference Endotoxin (CCRE) Versus Placebo(ENDOHEART)

NCT03623022

COMPLETED NA

Effect of Cross Frequency tACS on Cognitive Control

NCT03800030

COMPLETED NA

Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics

NCT03556683

COMPLETED NA

North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2

NCT03548779

COMPLETED NA

Single Session of tACS in a Depressive Episode

NCT03449979

COMPLETED

ADPKD Alterations in Hepatic Transporter Function

NCT03717883

COMPLETED NA

Priming Through Timing. Using Opposing Strategies to Enhance Motor Learning for Individuals With Parkinson's Disease

NCT03660605

COMPLETED NA

Improving African American Glaucoma Patient Involvement in Visits and Outcomes

NCT03657147

COMPLETED NA

Innovation in Postpartum Care for Women With Hypertensive Disorders of Pregnancy

NCT03613714

COMPLETED NA

Mechanisms of Manual Therapies in CAI Patients

NCT03418051

COMPLETED NA

Modulation of Motor Cortex Excitability by TMS and tDCS (MAGS1)

NCT03481309

COMPLETED NA

Vitamin C Supplementation Intervention

NCT04036110

COMPLETED Phase 4

Clinical Trial Comparing Effectiveness of Buffered Versus Unbuffered Local Anesthetic in Children Ages 10-12 Years

NCT03562481

TERMINATED Phase 2

Vitamin D and n-3 Polyunsaturated Fatty Acids (PUFAs) to Prevent Chronic Pain Following Major Thermal Burn Injury

NCT03313076

COMPLETED NA

LC Bead LUMI for Prostatic Artery Embolization

NCT03372096

COMPLETED NA

A Study of the Feasibility of Prehospital Remote Ischemic Conditioning

NCT03400579

COMPLETED NA

Bleach vs. Bubbles: Assessing the Impact of the Bathroom Environment on Eczema

NCT03619161

COMPLETED NA

Study of an International Commercial Program on Weight Loss and Health Outcomes

NCT03571893

COMPLETED Phase 2

A Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults

NCT03444298

COMPLETED Early Phase 1

Comparison of 129Xe MRI With 19F MRI in CF Lung Disease

NCT03482960

COMPLETED NA

Geniculate Artery Embolization for Knee Pain Secondary to Osteoarthritis (OA)

NCT03362957

COMPLETED NA

Outcomes in Children With Pre-operative Residual Hearing

NCT03379870

COMPLETED NA

Patient and Family Partners in Heart Failure Care: Pilot Test of a Pre-visit Question Prompt List to Enhance Engagement During Medical Visits

NCT03491800

COMPLETED NA

Impact of Sugar-Sweetened Beverage Health Warnings

NCT03511937

COMPLETED NA

Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination

NCT03442062

COMPLETED NA

4-week Mindfulness Program for Adults With Chronic Pain

NCT03495856

COMPLETED NA

Conventional Bite Wing Radiography Versus Stationary Intraoral Tomosynthesis, a Comparison Study

NCT02873585

COMPLETED NA

University of North Carolina-Healthwise Partnership Project on Birth Options Decision Aid

NCT04053413

← Previous Page 9 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 111
Phase 2 92
Phase 3 13
Phase 4 56

What is open in the University of North Carolina, Chapel Hill pipeline

108 recruiting of 1,109 indexed (10% open); 881 completed (79%).

Phase mix: 69 late (III/IV) vs 203 early (I/II) (early-phase heavy).

Top condition: Obesity (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of North Carolina, Chapel Hill: open-pipeline peers nationwide

Peers matched on 1,109 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share University of North Carolina, Chapel HillUniversity of FloridaWake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthChildren's Hospitals and Clinics of MinnesotaCytokineticsSanofiOhio University
University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,109 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

What to do with this University of North Carolina, Chapel Hill page

1,109 registered trials is a research-attention snapshot, not an endorsement of University of North Carolina, Chapel Hill or any single study.

  • 108 of University of North Carolina, Chapel Hill's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of North Carolina, Chapel Hill studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of North Carolina, Chapel Hill pipeline card: 1,109 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.